NCT03839355View on ClinicalTrials.gov

Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation

PHASE3TerminatedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

December 19, 2018

Primary Completion Date

December 15, 2020

Study Completion Date

December 15, 2020

Conditions
Atrial Fibrillation
Interventions
DRUG

Apixaban

Dosage either 5mg or 2.5mg for 2 years

DRUG

Warfarin

Dosage assessed by your treating physician for 2 years

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Mayo Clinic

OTHER